Drug · CHEMBL778
DEXMEDETOMIDINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DEXMEDETOMIDINE. Drugs and targets, record CHEMBL778. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL778
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRA2A | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 agonist | AGONIST | https://conductscience.org/library/genes/150 |
| ADRA2B | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 agonist | AGONIST | https://conductscience.org/library/genes/151 |
| ADRA2C | Adrenergic receptor alpha-2 | Adrenergic receptor alpha-2 agonist | AGONIST | https://conductscience.org/library/genes/152 |
Source ChEMBL
Diseases145
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 145Source Open Targets
See all 145 diseasesTrials1,795
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 2 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 6 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02004613 | Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery | Phase 4 | 798 | 2021-04-06 | dexmedetomidine | Its name | ClinicalTrials.gov |
| NCT02856594 | Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep | Phase 2/3 | 469 | 2023-03-20 | dexmedetomidine | Its name | ClinicalTrials.gov |
| NCT01739933 | The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure | Phase 3 | 438 | 2021-06-07 | dexmedetomidine | Its name | ClinicalTrials.gov |
| NCT01528891 | Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation | Phase 3 | 418 | 2015-11-25 | dexmedetomidine | Its name | ClinicalTrials.gov |
| NCT00561678 | Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve | Phase 4 | 404 | 2017-03-29 | dexmedetomidine | Its name | ClinicalTrials.gov |
| NCT04268303 | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia | Phase 3 | 380 | 2023-06-18 | dexmedetomidine | Its name | ClinicalTrials.gov |
| NCT04276883 | Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder | Phase 3 | 380 | 2023-09-11 | dexmedetomidine | Its name | ClinicalTrials.gov |
| NCT01973452 | Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery | Phase 3 | 333 | 2024-02-20 | dexmedetomidine | Its name | ClinicalTrials.gov |
| NCT02267538 | Dexmedetomidine and Delirium in Patients After Cardiac Surgery | Phase 4 | 285 | 2018-02-05 | dexmedetomidine | Its name | ClinicalTrials.gov |
| NCT04470050 | Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal | Phase 1/2 | 225 | 2023-10-26 | dexmedetomidine | Its name | ClinicalTrials.gov |
1 to 10 of 1,795
See all 1,795 trialsComparisons in its trials237
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dexmedetomidine vs Placebo: Number of Patients With Atrial Arrhythmia | 121 of 397 | 134 of 395 | 792 | NCT02004613 | Trial comparisons |
| Dexmedetomidine vs Placebo: deaths from any cause | 1 of 394 | 1 of 390 | 784 | NCT02004613 | Trial comparisons |
| Dexmedetomidine vs Placebo: serious adverse events | 21 of 394 | 8 of 390 | 784 | NCT02004613 | Trial comparisons |
| Dexmedetomidine vs Placebo: Number of Patients With Delirium | 67 of 389 | 46 of 387 | 776 | NCT02004613 | Trial comparisons |
| Dexmedetomidine vs Placebo: Number of Patients With Incisional Pain | 79 of 289 | 93 of 300 | 589 | NCT02004613 | Trial comparisons |
| Dexmedetomidine vs Propofol: Death at 90 Days | 81 of 214 | 82 of 208 | 422 | NCT01739933 | Trial comparisons |
| Dexmedetomidine vs Propofol: deaths from any cause | 89 of 214 | 86 of 208 | 422 | NCT01739933 | Trial comparisons |
| Dexmedetomidine vs Propofol: serious adverse events | 0 of 214 | 0 of 208 | 422 | NCT01739933 | Trial comparisons |
| Dexmedetomidine vs Placebo: serious adverse events | 1 of 200 | 0 of 200 | 400 | NCT01528891 | Trial comparisons |
| Dexmedetomidine-induced Sleep vs Placebo: deaths from any cause | 4 of 188 | 4 of 206 | 394 | NCT02856594 | Trial comparisons |
1 to 10 of 237
See all 237 comparisons in its trialsPapers from its trials955
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials15
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Psychomotor Vigilance Task | 5 | 0 | ConductCognition |
| Digit Span Test | 3 | 2 | ConductCognition |
| Trail Making Test A | 3 | 2 | ConductCognition |
| Trail Making Test B | 3 | 2 | ConductCognition |
| Verbal Learning | 3 | 2 | ConductCognition |
| Verbal Fluency | 2 | 1 | ConductCognition |
| Block Copy Test | 1 | 1 | ConductCognition |
| Dimensional Change Card Sort | 1 | 0 | ConductCognition |
| Category Fluency | 1 | 1 | ConductCognition |
| Clock Drawing Task | 1 | 1 | ConductCognition |
1 to 10 of 15
See all 15 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL778
GET https://conductscience.org/api/drugs/v1/CHEMBL778/diseases?page=2